Drugs / LISINOPRIL ANHYDROUS
LISINOPRIL ANHYDROUS
also known as
Lisinopril · Zestril · Carace · Diroton · Lisinopril component of prinzide · Lisinopril component of zestoretic · Lisinopril dihydrate · LISINOPRIL HYDRATE · +8 more
Small molecule targets ACE via inhibition
Regulatory milestones approvals, filings & regulatory actions · 5 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Label expansion | US (FDA) | PRINIVIL | — | 2003-05-29 | fda.gov ↗ |
| Label expansions (3) | US (FDA) | ZESTRIL | — | 1993-06-09 – 2000-02-07 | fda.gov ↗ |
| Approved | US (FDA) | PRINIVIL | — | 1987-12-29 | fda.gov ↗ |
Trials 65 · started per year
today
US approved 1987
3
1
2
1
3
4
3
7
3
2
5
4
4
2
3
2
4
3
2
2
3
2
198719881989199019911992199319941995199619971998199920002001200220032004200520062007200820092010201120122013201420152016201720182019202020212022202320242025202620272028
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT05530655 | Feb 2024 → Jan 2028 expected | prostate cancer, radiation-induced disorder | University of Rochester | Recruiting | No outcome recorded |
| Phase 115 trials · 1 missed | ||||||
| Phase 1 | NCT06772779 | Apr → Jun 2024 | — | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 1 | NCT02641899 | Dec 2015 → Mar 2016 | — | Intarcia Therapeutics | Completed | No outcome recorded |
| Phase 1 | NCT02232308 | Jul → Sep 2014 | gastroparesis | Adil Bharucha | Completed | No outcome recorded |
| Phase 1 | NCT02070510 | Feb → Aug 2014 | diabetes mellitus | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 1 | NCT01491919 | Jun 2012 → Sep 2013 | hypertensive disorder | Uptal Patel | Completed | No outcome recorded |
| Phase 1 | NCT01398267 | Aug 2011 → Oct 2012 | type 2 diabetes mellitus | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase 1 | NCT01324388 | Mar → Aug 2011 | type 2 diabetes mellitus | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 1 | NCT01066572 | Oct 2010 → Dec 2011 | stroke disorder | Newcastle-upon-Tyne Hospitals NHS Trust | Completed | No outcome recorded |
| Phase 1 | NCT00557128 | Nov → Dec 2007 | hypertensive disorder | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 1 | NCT00549510 | Oct → Dec 2007 | hypertensive disorder | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 1 | NCT00537043 | Oct 2007 → Jan 2008 | essential hypertension | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 1 | NCT00508365 | Sep 2007 → Jun 2008 | hypertensive disorder | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 1 | NCT01518166 | May 2006 → Apr 2007 | type 2 diabetes mellitus | Novo Nordisk A/S | Completed | Missed primary |
| Phase 1 | NCT01380431 | Aug → Oct 1999 | — | Par Pharmaceutical, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT01375244 | Jun → Oct 1999 | — | Par Pharmaceutical, Inc. | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT00553969 | Nov 2007 → Sep 2010 | hypertensive disorder | University of Minnesota | Completed | No outcome recorded |
| Phase 211 trials · 1 missed | ||||||
| Phase 2 | NCT07685938 | Aug 2026 → Feb 2029 expected | breast cancer, esophageal cancer, lung cancer, mediastinal cancer +2 | UNC Lineberger Comprehensive Cancer Center | Recruiting | No outcome recorded |
| Phase 2 | NCT03422705 | Dec 2022 | — | University of Leeds | Unknown | No outcome recorded |
| Phase 2 | NCT04977180 | Mar 2022 → Mar 2028 expected | acute myeloid leukemia | University of Virginia | Recruiting | No outcome recorded |
| Phase 2 | NCT04550481 | May 2021 → Aug 2025 overdue | hepatocellular carcinoma, metabolic dysfunction-associated steatohepatitis | Northwestern University | Active not recruiting | No outcome recorded |
| Phase 2 | NCT02682459 | Feb 2016 → Sep 2019 | glomerulonephritis | Monia Lorini | Unknown | No outcome recorded |
| Phase 2 | NCT01880528 | May → Jun 2013 | non-small cell lung carcinoma, small cell lung carcinoma | Mayo Clinic | Completed | No outcome recorded |
| Phase 2 | NCT01234922 | Feb 2011 → Dec 2013 | cancer of unknown primary site, hypertensive disorder | Wake Forest University Health Sciences | Terminated | No outcome recorded Stop: Enrollment |
| Phase 2 | NCT01009918 | Mar 2010 → Aug 2017 | breast cancer, poisoning | University of South Florida | Completed | No outcome recorded |
| Phase 2 | NCT00567307 | Jan → Dec 2009 | cardiovascular disorder | Wake Forest University Health Sciences | Completed | Missed primary |
| Phase 2 | NCT00605072 | Jan 2008 → Dec 2011 | cognitive impairment with or without cerebellar ataxia, hypertensive disorder | University of Southern California | Completed | Mixed |
| Phase 2 | NCT01409837 | Mar 1998 → Dec 2006 | oligospermia | University Of Nigeria Teaching Hospital | Completed | No outcome recorded |
| Phase 312 trials · 1 met primary · 6 missed | ||||||
| Phase 3 | NCT02735707 | Apr 2016 → Feb 2026 overdue | pneumonia | UMC Utrecht | Recruiting | Mixed |
| Phase 3 | NCT01313702 | Oct 2012 → Apr 2014 | cardiovascular disorder | Hospital do Coracao | Withdrawn | No outcome recorded |
| Phase 3 | NCT01326676 | Feb 2011 → Jul 2012 | cardiovascular disorder | Imperial College London | Withdrawn | No outcome recorded Stop: Business |
| Phase 3 | NCT01057537 | Jun 2010 → Jul 2012 | cardiovascular disorder | Imperial College London | Completed | Met primary |
| Phase 3 | NCT00555217 | Jul 2008 → Sep 2014 | kidney disorder, type 2 diabetes mellitus | US Department of Veterans Affairs | Terminated | Missed primary |
| Phase 3 | NCT00624065 | Mar → Aug 2008 | essential hypertension | GlaxoSmithKline | Completed | Missed primary |
| Phase 3 | NCT00347360 | Jul 2006 → Apr 2008 | hypertensive disorder | GlaxoSmithKline | Completed | Missed primary |
| Phase 3 | NCT00582114 | Aug 2005 → Sep 2013 | essential hypertension, heart disorder | Indiana University | Terminated | Missed primary |
| Phase 3 | NCT00108082 | Jan 2005 → Aug 2008 | heart disorder | GlaxoSmithKline | Completed | Missed primary |
| Phase 3 | NCT00171067 | Jul 2004 → May 2007 | hypertensive disorder | Novartis | Completed | No outcome recorded |
| Phase 3 | NCT00000542 | Aug 1993 → Mar 2002 | coronary artery disorder, diabetes mellitus, heart failure, hyperlipidemia +3 | National Heart, Lung, and Blood Institute (NHLBI) | Completed | Missed primary |
| Phase 3 | NCT00004266 | Aug 1993 → Jul 1999 | diabetic kidney disease | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | Completed | No outcome recorded |
| Phase 416 trials · 1 met primary · 1 missed | ||||||
| Phase 4 | NCT07594535 | Jul 2026 → Jul 2028 expected | polycythemia | Mayo Clinic | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT05049616 | Oct 2021 → Jun 2022 | preeclampsia | The University of Texas Health Science Center, Houston | Completed | No outcome recorded |
| Phase 4 | NCT03461003 | Apr 2018 → Nov 2020 | early onset hypertension | The University of Texas Health Science Center, Houston | Completed | No outcome recorded |
| Phase 4 | NCT03392740 | Mar → Dec 2018 | cardiomyopathy due to anthracyclines, systolic heart failure | Ascension Health | Withdrawn | No outcome recorded |
| Phase 4 | NCT03417388 | Feb 2018 → Sep 2026 overdue | nonobstructive coronary artery disease | Cedars-Sinai Medical Center | Active not recruiting | Missed primary |
| Phase 4 | NCT02847338 | Nov 2016 → Oct 2023 | hypertensive disorder | Cambridge University Hospitals NHS Foundation Trust | Completed | No outcome recorded |
| Phase 4 | NCT02817360 | Feb 2016 → Dec 2025 overdue | heart disorder, type 2 diabetes mellitus | Martin Huelsmann | Recruiting | No outcome recorded |
| Phase 4 | NCT01669434 | Jun 2015 → Nov 2016 | — | University of Nebraska | Completed | Met primary |
| Phase 4 | NCT02184858 | Jun 2014 → May 2017 | essential hypertension, secondary hypertension | University Ghent | Completed | No outcome recorded |
| Phase 4 | NCT01218100 | Oct 2010 → May 2011 | hypertensive disorder | Forest Laboratories | Completed | No outcome recorded |
| Phase 4 | NCT02358642 | Sep 2010 → Dec 2012 | pneumonia | Chinese University of Hong Kong | Terminated | No outcome recorded |
| Phase 4 | NCT00430040 | Feb 2007 → May 2013 | hypertensive disorder, type 2 diabetes mellitus | University at Buffalo | Terminated | No outcome recorded |
| Phase 4 | NCT00171600 | Jul 2005 → Jan 2007 | diabetic kidney disease, hypertensive disorder | Novartis | Terminated | No outcome recorded |
| Phase 4 | NCT00171574 | Nov 2004 → Jul 2006 | diabetic kidney disease, hypertensive disorder | Novartis | Completed | No outcome recorded |
| Phase 4 | NCT00241124 | Apr 2004 → Jun 2005 | hypertensive disorder | Novartis | Completed | No outcome recorded |
| Phase 4 | NCT00311870 | Mar 1993 → Apr 1999 | diabetic kidney disease | Steno Diabetes Center Copenhagen | Completed | No outcome recorded |
| Phase not applicable9 trials · 1 met primary · 1 missed | ||||||
| — | NCT06187493 | Jan 2024 → Jan 2025 | diabetic kidney disease | Assiut University | Unknown | No outcome recorded |
| — | NCT01867047 | Jun 2013 → Jun 2016 | hypotensive disorder | Duke University | Terminated | Missed primary |
| — | NCT01691781 | Oct 2012 → Aug 2016 | primary hyperparathyroidism | Brigham and Women's Hospital | Completed | Met primary |
| — | NCT01506505 | Jul 2012 → Jul 2013 | cerebrovascular disorder, peripheral arterial disease | UMC Utrecht | Completed | Mixed |
| — | NCT00982189 | Sep 2009 → Dec 2010 | HIV infectious disease, cardiovascular disorder | Hennepin Healthcare Research Institute | Completed | No outcome recorded |
| — | NCT01009944 | Jan 2007 → Mar 2019 | hypertensive disorder | Brigham and Women's Hospital | Withdrawn | No outcome recorded Stop: Business |
| — | NCT00337298 | Jul 2006 → Feb 2009 | diabetic retinopathy, type 1 diabetes mellitus | University of Aarhus | Completed | No outcome recorded |
| — | NCT00118976 | Mar 2005 → Sep 2006 | diabetic kidney disease, type 1 diabetes mellitus | Steno Diabetes Center Copenhagen | Completed | No outcome recorded |
| — | NCT00151138 | Sep 2002 → May 2007 | hypertensive disorder | University of Pittsburgh | Completed | No outcome recorded |
| Comparator or background therapy50 trials | ||||||
| Phase 1 | NCT02623036 Comparator | Nov 2015 → Apr 2018 | resistant hypertension | Memorial Health University Medical Center | Unknown | No outcome recorded |
| Phase 2 | NCT04486118 Comparator | Oct 2021 → Jun 2025 overdue | systemic lupus erythematosus | Northwell Health | Active not recruiting | No outcome recorded |
| Phase 2 | NCT03201939 Comparator | Apr → Nov 2021 | HIV infectious disease, proteinuria | Vanderbilt University Medical Center | Terminated | No outcome recorded |
| Phase 2 | NCT04190433 Background | Sep 2020 → Apr 2023 | breast carcinoma, lymphoma, sarcoma | Mayo Clinic | Withdrawn | No outcome recorded Stop: Enrollment |
| Phase 2 | NCT02603809 Comparator | Dec 2015 → Feb 2017 | essential hypertension | Idorsia Pharmaceuticals Ltd. | Completed | Met primary |
| Phase 2 | NCT01984164 Comparator | Aug 2014 → Dec 2018 | cognitive impairment with or without cerebellar ataxia, hypertensive disorder | Emory University | Completed | No outcome recorded |
| Phase 2 | NCT01901549 Comparator | Jun 2013 → Jun 2015 | acute coronary syndrome, hypertensive disorder | Meshalkin Research Institute of Pathology of Circulation | Unknown | No outcome recorded |
| Phase 2 | NCT00874432 Comparator | Jan → Dec 2009 | cardiovascular disorder, chronic kidney disease | University of Wisconsin, Madison | Completed | No outcome recorded |
| Phase 2 | NCT00814255 Comparator | Dec 2008 → Jun 2013 | focal segmental glomerulosclerosis | NYU Langone Health | Completed | No outcome recorded |
| Phase 2/3 | NCT01126697 Comparator | Feb 2010 → Dec 2017 | Becker muscular dystrophy, Duchenne muscular dystrophy, limb-girdle muscular dystrophy | Cooperative International Neuromuscular Research Group | Completed | No outcome recorded |
| Phase 3 | NCT05056727 Background | Sep 2021 → Feb 2024 | chronic kidney disease | AstraZeneca | Terminated | Missed primary Stop: Enrollment |
| Phase 3 | NCT01437371 Background | Aug 2011 → Jun 2014 | heart failure | University Hospital, Clermont-Ferrand | Completed | No outcome recorded |
| Phase 3 | NCT00280215 Comparator | Dec 2007 → Dec 2011 | primary hyperoxaluria | Mayo Clinic | Withdrawn | No outcome recorded Stop: Business |
| Phase 3 | NCT00459056 Background | Apr 2007 → May 2010 | abdominal obesity-metabolic syndrome, hypertensive disorder | St. Paul Heart Clinic | Completed | No outcome recorded |
| Phase 3 | NCT00283686 Comparator | Jan 2006 → Jun 2014 | autosomal dominant polycystic kidney disease | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | Completed | No outcome recorded |
| Phase 3 | NCT01885559 Comparator | Jan 2006 → Jun 2014 | autosomal dominant polycystic kidney disease | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | Completed | No outcome recorded |
| Phase 3 | NCT00123903 Background | Jul 2005 → May 2006 | congestive heart failure | GlaxoSmithKline | Terminated | No outcome recorded |
| Phase 4 | NCT07547878 Comparator | Apr 2026 → Mar 2029 expected | chronic kidney disease, type 2 diabetes mellitus | Baylor Research Institute | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT07513883 Background | Mar 2026 → Sep 2028 expected | heart failure | Ziekenhuis Oost-Limburg | Recruiting | No outcome recorded |
| Phase 4 | NCT04662723 Background | May 2023 → Jun 2026 overdue | IgA glomerulonephritis | Schena Foundation | Recruiting | No outcome recorded |
| Phase 4 | NCT05644769 Comparator | Nov 2022 → Mar 2023 | hypertensive disorder | Trinity Hypertension & Metabolic Research Institute | Unknown | No outcome recorded |
| Phase 4 | NCT04330300 Comparator | Apr 2020 → Jul 2021 | COVID-19, essential hypertension | National University of Ireland, Galway, Ireland | Suspended | No outcome recorded Stop: Business |
| Phase 4 | NCT03502031 Comparator | Oct 2018 → Oct 2022 | diabetic kidney disease | James A. Tumlin, MD | Unknown | No outcome recorded |
| Phase 4 | NCT02774460 Comparator | Feb 2017 → Jun 2021 | hypertensive disorder | Uppsala University | Completed | No outcome recorded |
| Phase 4 | NCT03195023 Comparator | Jun 2015 → Dec 2019 | chronic kidney disease, proteinuria | Hospital General Universitario Gregorio Marañon | Unknown | No outcome recorded |
| Phase 4 | NCT02200822 Comparator | Jul 2014 → Feb 2019 | heart failure | Hasselt University | Completed | No outcome recorded |
| Phase 4 | NCT01837069 Comparator | Feb 2014 → Apr 2018 | cardiovascular disorder, osteoarthritis | NYU Langone Health | Terminated | No outcome recorded Stop: Enrollment |
| Phase 4 | NCT01774656 Background | Jan 2013 → Dec 2017 | advanced heart failure | University of Louisville | Unknown | No outcome recorded |
| Phase 4 | NCT01535235 Comparator | Feb 2012 → Dec 2014 | HIV infectious disease | University of California, San Francisco | Completed | No outcome recorded |
| Phase 4 | NCT01700075 Comparator | Jan → Dec 2009 | atherosclerosis, coronary artery disorder, myocardial infarction, type 2 diabetes mellitus | Nazarbayev University | Completed | No outcome recorded |
| Phase 4 | NCT00741585 Comparator | Sep 2008 → Jun 2018 | chronic kidney disease, essential hypertension, stroke disorder | University of Vigo | Completed | No outcome recorded |
| Phase 4 | NCT00673790 Comparator | May 2008 → Jul 2010 | hypertensive disorder | Forest Laboratories | Completed | No outcome recorded |
| Phase 4 | NCT00391846 Background | Oct 2006 → Jan 2009 | left ventricular failure | AstraZeneca | Completed | No outcome recorded |
| Phase 4 | NCT02441842 Comparator | Mar 2006 → Dec 2008 | malignant secondary hypertension | Milton S. Hershey Medical Center | Completed | No outcome recorded |
| Phase 4 | NCT00661895 Background | Aug 2005 → Aug 2009 | hypertensive disorder | Creighton University | Completed | No outcome recorded |
| Phase 4 | NCT00295542 Comparator | Mar 2000 → Apr 2009 | hypertensive disorder | University of Vigo | Completed | No outcome recorded |
| — | NCT07568574 Background | Mar 2026 → May 2028 expected | — | Enhanced Emirates Limited | Enrolling by invitation | No outcome recorded |
| — | NCT05016440 Comparator | Sep 2015 | preeclampsia, proteinuria | Eastern Virginia Medical School | Withdrawn | No outcome recorded |
| — | NCT02412761 Comparator | Jun 2013 → Jul 2016 | essential hypertension | The University of Texas Health Science Center, Houston | Completed | No outcome recorded |
| — | NCT01996085 Comparator | Jan 2013 → Jun 2016 | hypertensive disorder | Military Institute od Medicine National Research Institute | Completed | No outcome recorded |
| — | NCT01658657 Comparator | Oct 2012 → Jul 2014 | hypertensive disorder, proteolytic capacity of plasma | University of North Carolina, Chapel Hill | Completed | No outcome recorded |
| — | NCT01258764 Comparator | Nov 2010 → Mar 2014 | hypertensive disorder | Scripps Translational Science Institute | Completed | No outcome recorded |
| — | NCT01076140 Comparator | Feb 2010 → Jan 2011 | hypertensive disorder | University of Mississippi Medical Center | Withdrawn | No outcome recorded Stop: Enrollment |
| — | NCT01101269 Comparator | Feb 2010 → Dec 2014 | type 2 diabetes mellitus | University of Virginia | Terminated | No outcome recorded Stop: Enrollment |
| — | NCT01982695 Comparator | Mar 2009 → Aug 2012 | Duchenne muscular dystrophy, cardiomyopathy | Nationwide Children's Hospital | Completed | No outcome recorded |
| — | NCT00773084 Comparator | Sep 2008 → Aug 2009 | diastolic heart failure | Texas Tech University Health Sciences Center | Withdrawn | No outcome recorded Stop: Enrollment |
| — | NCT00743197 Comparator | May 2008 → May 2010 | intermediate coronary syndrome | Northwestern University | Terminated | No outcome recorded |
| — | NCT00292162 Comparator | Jan 2007 → Jul 2009 | atrial fibrillation, heart failure | NHS Greater Glasgow and Clyde | Completed | No outcome recorded |
| — | NCT02336607 Comparator | Dec 2005 → Jun 2006 | hypertensive disorder | AstraZeneca | Completed | No outcome recorded |
| — | NCT00684489 Comparator | Sep 2003 → Mar 2005 | essential hypertension | Medical University of South Carolina | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2002-07-01 | Teva Branded Pharmaceutical Products R&D, Inc. | Regulatory Teva Announces Approval of Lisinopril Tablets and Lisinopril HCTZ Tablets tevapharm.com ↗
has issued final approval for the company's ANDA for Lisinopril Tablets USP, 2.5 mg, 5 mg, 10 mg, 20 mg, 30 mg and 40 mg as well as its ANDA for Lisinopril and Hydrochlorothiazide Tablets |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2002-07-01 | Teva Branded Pharmaceutical Products R&D, Inc. | Teva Announces Approval of Lisinopril Tablets and Lisinopril HCTZ Tablets tevapharm.com ↗ |
Evidence & citations 21 cited values
Every value below carries the sentence it was read from. 117 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | LISINOPRIL ANHYDROUS | ChEMBL registry synonym — accepted as the source's own label CHEMBL1237 ↗ |
| Known as | Carace | ChEMBL registry synonym — accepted as the source's own label CHEMBL1237 ↗ |
| Known as | Diroton | “Antihypertensive: "Diroton" (Lisinopril, Gedeon Richter Ltd) - 10mg twice per day” NCT01700075 ↗ |
| Known as | Lisinopril | “The pharmacological treatment intended to enhance reverse remodeling includes 4 drugs initiated immediately after weaning of inotropic support once achieving adequate end-organ...” NCT01774656 ↗113“Examples of possible ACE-I drugs include: benazepril (Lotensin), captopril (Capoten), enalapril (Vasotec, Epaned), fosinopril (Monopril), lisinopril (Prinivil, Zestril),...” NCT01867047 ↗ “This study is to compare carvedilol controlled release to carvedilol controlled release plus lisinopril (fixed-dose combination) after repeat dosing in patients with high blood...” NCT00537043 ↗ “Version 1 contains aspirin 75mg, simvastatin 40mg, Lisinopril 10mg and Atenolol 50mg; Version 2 contains aspirin 75mg, simvastatin 40mg, Lisinopril 10mg and Hydrochlorothiazide 12.5mg.” NCT01326676 ↗ “Version 1 contains aspirin 75mg, simvastatin 40mg, Lisinopril 10mg and Atenolol 50mg; Version 2 contains aspirin 75mg, simvastatin 40mg, Lisinopril 10mg and Hydrochlorothiazide 12.5mg.” NCT01057537 ↗ “RAAS (Lisinopril, Enalapril, Perindopril, Losartan, and Valsartan taken each day at maximum tolerated dose that will different for each subject)” NCT03502031 ↗ “The trial compared a Polypill (75 mg aspirin, 20 mg simvastatin, 10 mg lisinopril and 12.5 mg hydrochlorothiazide) to Standard Practice.” PMID 21205325 ↗ Jan 2011 “the cardiovascular polypill (aspirin 75 mg, simvastatin 40 mg, lisinopril 10 mg, and hydrochlorothiazide 12.5 mg) in the evening” PMID 23382539 ↗ Feb 2013 “Benazepril, captopril, enalapril, fosinopril, lisinopril, perindopril, quinapril, ramipril, trandolapril” NCT04330300 ↗ “either a combined pill of ACE inhibitors and diuretics (Hydrochlorothiazide/Lisinopril)” NCT05049616 ↗ “Preventive beta blocker (metoprolol or carvedilol) and an ACE inhibitor (lisinopril)” NCT04977180 ↗ |
| Known as | Lisinopril component of prinzide | ChEMBL registry synonym — accepted as the source's own label CHEMBL1237 ↗ |
| Known as | Lisinopril component of zestoretic | ChEMBL registry synonym — accepted as the source's own label CHEMBL1237 ↗ |
| Known as | Lisinopril dihydrate | ChEMBL registry synonym — accepted as the source's own label CHEMBL1237 ↗ |
| Known as | LISINOPRIL HYDRATE | ChEMBL registry synonym — accepted as the source's own label CHEMBL1237 ↗ |
| Known as | Lisopress | ChEMBL registry synonym — accepted as the source's own label CHEMBL1237 ↗ |
| Known as | MK-521 | ChEMBL registry synonym — accepted as the source's own label CHEMBL1237 ↗ |
| Known as | NSC-751176 | ChEMBL registry synonym — accepted as the source's own label CHEMBL1237 ↗ |
| Known as | NSC-758151 | ChEMBL registry synonym — accepted as the source's own label CHEMBL1237 ↗ |
| Known as | Prinivil | “Examples of possible ACE-I drugs include: benazepril (Lotensin), captopril (Capoten), enalapril (Vasotec, Epaned), fosinopril (Monopril), lisinopril (Prinivil, Zestril),...” NCT01867047 ↗ |
| Known as | Prinivil, Zestril (Lisinopril) | “Prinivil, Zestril (Lisinopril)” NCT01009944 ↗ |
| Known as | Qbrelis | ChEMBL registry synonym — accepted as the source's own label CHEMBL1237 ↗ |
| Known as | Ranolip | ChEMBL registry synonym — accepted as the source's own label CHEMBL1237 ↗ |
| Known as | Zestril | “Examples of possible ACE-I drugs include:
benazepril (Lotensin), captopril (Capoten), enalapril (Vasotec, Epaned), fosinopril (Monopril), lisinopril (Prinivil, Zestril),...” NCT01867047 ↗3“10mg, 20mg, or 40mg QD Doses of Lisinopril (Zestril) or a Combination” NCT00347360 ↗ “Lisinopril (Zestril) 10mg, once daily.” NCT02336607 ↗ |
| Action | Inhibit | “lisinopril, an angiotensin-converting enzyme inhibitor” PMID 24842697 ↗ Jul 2014 |
| Modality | Small molecule | — CHEMBL1237 ↗ |
| Route | Oral | “Oral medication.” NCT00459056 ↗ |
| Target | ACE | “the ACE inhibitor, lisinopril: 20, 40 and 60 mg daily” NCT00118976 ↗ |